Mihaela Jorgovan

Mrs. Mihaela Jorgovan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
TMTamara Maksimovic
Tamara Maksimovic
CGCarmen Gădău
Carmen Gădău
GAGabriela Antal
Gabriela Antal
MJMihaela Jorgovan
Mihaela Jorgovan
OBOana Maria Bătrîna
Oana Maria Bătrîna
Codruta SoicaCodruta Soica
Codruta Soica
Aging, a progressive and time-dependent decline in physiological functions, is driven by interconnected hallmarks, among which mitochondrial dysfunction plays a central role. Mitochondria not only regulate energy production but also play key roles in other cellular processes, including ROS generation, apoptosis, and metabolic signaling—all of which decline with aging. Polyphenols are a diverse group of natural compounds found in fruits, vegetables, tea, and wine; they emerged as promising anti-aging agents due to their ability to modulate several hallmarks of aging, particularly mitochondrial dysfunction. This review explores how various polyphenolic classes influence mitochondrial function and mitigate aging-related decline. These natural compounds have been shown to reduce oxidative stress, increase energy production, and help maintain normal mitochondrial structure. Moreover, in vitro and in vivo studies suggest that polyphenols can delay signs of aging and improve physical and cognitive functions. Overall, polyphenols show great potential to promote healthy aging and even delay the decline in physiological functions by protecting and enhancing mitochondrial health.

29 September 2025 in Molecules
Verified
Journal Article
Open access
PDF file
MMMarius Mioc
Marius Mioc
SGSilvia Milița Gruin
Silvia Milița Gruin
Armand GogulescuArmand Gogulescu
Armand Gogulescu
OBOana Maria Bătrîna
Oana Maria Bătrîna
MJMihaela Jorgovan
Mihaela Jorgovan
Codruta SoicaCodruta Soica
Codruta Soica
Anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, and Mcl-1), are often overexpressed in cancer, which aids tumor growth and treatment resistance. As a result, these proteins are excellent candidates for novel anticancer drugs. Within this study a virtual library of betuline derivatives was built and screened for possible Bcl-2, Bcl-XL, and Mcl-1 inhibitors. For every target, molecular docking simulations were performed using two different engines (AutoDock Vina and Glide). The ligands that most frequently appeared among the top candidates were shortlisted after comparing the top-20 hits from both docking scoring functions. To assess binding stability, five of these promising compounds were chosen and run through 100 ns molecular dynamics (MD) simulations in complex with every target protein. Key persistent intermolecular contacts were identified from MD contact frequency histograms, and stability was evaluated using root-mean-square deviation (RMSD) profiles of protein–ligand complexes following equilibration. Additionally, Prime MM-GBSA binding energies (ΔG_bind) for the 15 docked complexes were computed, and ligand efficiency was reported. Two substances, BOxNaf1 and BT3, stood out among the screened derivatives as the most stable binders to all three Bcl-2 family targets according to the dual docking and MD analysis approach. When the MM-GBSA and RMSF/rGyr data are considered alongside docking and MD stability, BOxNaf1 and BOxPhCl1 emerge as the most compelling dual/multi-target candidates, whereas BT3, though MD stable, shows weaker MM-GBSA energetics and is retained as a lower-priority backup chemotype.

Verified
Journal Article
Open access
PDF file
OBOana Maria Bătrîna
Oana Maria Bătrîna
RGRoxana Ghiulai
Roxana Ghiulai
LSLiana Suciu
Liana Suciu
Roxana Racoviceanu (Babuta)Roxana Racoviceanu (Babuta)
Roxana Racoviceanu (Babuta)
EAElisabeta Atyim
Elisabeta Atyim
MMMarius Mioc
Marius Mioc
Compounds of plant origin have increasingly emerged as anticancer agents through direct cytotoxicity and sensitizing mechanisms. Melanoma remains the most aggressive form of skin cancer that exhibits a steadily increasing number of new cases globally each year, thus urgently requiring more effective therapeutic strategies. Therefore, phytochemicals can be considered promising candidates, particularly when used in combination with immune checkpoint inhibitors. Their ability to optimize therapeutic efficacy and strengthen antitumor immune responses is mediated through various mechanisms that include the stimulation of T cell activity, the regulation of the TME, the activation of intrinsic immune responses and cytokine signaling, and the regulation of immune checkpoints such as PD-1/PD-L1, CTLA-4, and LAG-3. Additionally, these compounds can alter key signaling pathways that control immune regulation. Nevertheless, the extrapolation of preclinical studies to clinical applications remains limited by insufficient clinical evidence, the lack of standardized therapeutic protocols, and poor pharmacokinetic behavior. Consequently, further studies are required in order to clarify their actual efficacy and to better define their role in modern oncology. This article aims to review the mechanisms that underlie the anticancer sensitizing activity of major classes of plant-derived compounds such as polyphenols, flavonoids, terpenoids, alkaloids, and isothiocyanates. The available preclinical and clinical evidence were reported together with their potential synergistic effects when combined with immune checkpoint inhibitors. An important aspect related to the anticancer effects of these compounds lies in their ability to simultaneously target multiple signaling pathways. Furthermore, advanced formulations such as nanoparticulated delivery systems are discussed as strategies to optimize their clinical application and therapeutic outcomes.

30 December 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GMGabriel Ionel Mardale
Gabriel Ionel Mardale
APAlexandra Prodea
Alexandra Prodea
AMAndreea Munteanu
Andreea Munteanu
MJMihaela Jorgovan
Mihaela Jorgovan
EBElena Sabina Bilavu
Elena Sabina Bilavu
Codruta SoicaCodruta Soica
Codruta Soica
Background: A benzotriazole is a heterocycle frequently used in medicinal chemistry to obtain potent drug candidates, including anticancer agents. Nonetheless, the available literature lacks a comprehensive review of the in vitro and in vivo studies regarding these derivatives. Thus, our study aims to review the preclinical evidence on benzotriazole derivatives that showed potential as anticancer candidates, focusing on the cytotoxicity, mechanisms of action, structure–activity relationship, and methodological rigor of the included studies. Methods: We searched PubMed, Scopus, and Web of Science and included 41 studies in our analysis following the selection process. Additionally, we assessed the risk of bias using the QUIN tool for in vitro and the SYRCLE tool for in vivo studies in order to assess the methodological rigor of the included studies. Results: The benzotriazole derivatives were classified according to their structure in four classes, namely N-derivatives, C-derivatives, fused derivatives, and organometallic compounds. The in vitro results showed that certain derivatives, such as halogen, alkyl-aryl, or natural-base hybrids, can have superior cytotoxicity compared to parent molecules, exerted through multiple mechanisms, such as apoptosis and cell cycle arrest. Additionally, the in vivo analysis highlighted that benzotriazole derivatives can reduce tumor mass in a dose-dependent manner, with only a slight degree of hepatotoxicity reported in one case. However, histopathological data were generally absent or limited and based on a very limited number of in vivo studies. Conclusions: Overall, benzotriazole derivatives remain promising candidates for cancer treatment. However, limited mechanistic and toxicity data, as well as the moderate risk of bias identified across studies, may limit our assessment. Therefore, future studies should employ more rigorous methodologies and explore the underlying anticancer and toxicity mechanisms to fully assess the therapeutic potential of benzotriazole derivatives.

22 March 2026 in Biology
Verified
Journal Article
Open access
PDF file
MJMihaela Jorgovan
Mihaela Jorgovan
TMTamara Maksimovic
Tamara Maksimovic
OBOana Maria Bătrîna
Oana Maria Bătrîna
Codruta SoicaCodruta Soica
Codruta Soica
AMAlexandra Mioc
Alexandra Mioc
MMMarius Mioc
Marius Mioc
Cannabidiol is a non-psychoactive compound originating from Cannabis sativa L., with a promising therapeutic profile that influences numerous cellular processes. A major area of interest is its impact on mitochondria, organelles essential for cellular metabolism, ATP production, calcium homeostasis, and stress response. This article explores the available data on contribution of CBD effect on mitochondria to its therapeutic potential in treatment of various pathologies: cancer, cardiovascular, lung, neurological, gastrointestinal and liver disease, and muscle pathologies. Regarding cancer, the cytotoxic effects of cannabidiol on glioma, leukaemia, non-Hodgkin lymphoma, prostate, gastric, and breast cancer are analysed. In the case of cardiomyopathies and heart failure, cannabidiol plays an important role in reducing oxidative stress and promoting mitochondrial biogenesis. In lung diseases, cannabidiol reduces the expression of mitochondrial fission genes and increases the expression of fusion genes. When it comes to neurological pathologies, cannabidiol protects neurons and exhibits a strong antioxidant effect, while in gastrointestinal and liver diseases, cannabidiol stabilises mitochondrial membrane potential, increases ATP production, and reduces oxidative stress. In muscle affections, cannabidiol improves mitochondrial function by inhibiting excessive mitophagy. Although modern formulations may improve the low bioavailability of CBD, its potential non-selective cytotoxicity toward non-malignant cells remains an important concern that warrants further investigation. Nevertheless, cannabidiol possesses a remarkable therapeutic potential, and its effects on mitochondria open new perspectives in the treatment of numerous diseases.

5 September 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
SGSilvia Milița Gruin
Silvia Milița Gruin
AMAlexandra Mioc
Alexandra Mioc
Roxana Racoviceanu (Babuta)Roxana Racoviceanu (Babuta)
Roxana Racoviceanu (Babuta)
TMTamara Maksimovic
Tamara Maksimovic
MJMihaela Jorgovan
Mihaela Jorgovan
Codruta SoicaCodruta Soica
Codruta Soica
Cancer remains a leading cause of global mortality, entailing the exploration of novel therapeutic agents from natural sources. This study evaluated the in vitro anti-cancer potential of essential oils (EOs) extracted from the needles of Pinus sylvestris L. (Scots pine) and Picea abies (L.) H. Karst. (Norway spruce). GC–MS analysis revealed that both EOs are rich in monoterpenes; the primary constituents were α-pinene (35.27%) for Pinus sylvestris sylvestris EO (Pinus EO) and β-pinene (31.40%) for Picea abies EO (Picea EO). Cell viability assay (Alamar Blue) demonstrated that both EOs exert a dose-dependent cytotoxic effect across all tested malignant lines: melanoma (A375), colorectal adenocarcinoma (HT-29), and pancreatic adenocarcinoma (PANC-1). Notably, Pinus EO consistently displayed higher potency toward cancer cells when compared with normal keratinocytes (HaCaT), with the highest selectivity noticed in HT-29 cells. Immunofluorescence analysis revealed morphological changes consistent with apoptosis, such as nuclear condensation, DNA fragmentation, and the disruption of the β-actin cytoskeleton. High-resolution respirometry indicated that the EOs increase LEAK respiration, while also significantly reducing the oxidative phosphorylation (OXPHOS) efficiency. Furthermore, network pharmacology and molecular docking predicted EP300 as a common hub target for both EOs, with β-caryophyllene showing the most favourable predicted binding affinity among the investigated constituents. Overall, these preliminary in vitro and in silico findings support the further investigation of Pinus EO and Picea EO as potential candidates for the development of future adjuvant strategies in cancer therapy.